- ISIN
- US5560991094
- CUSIP
- 556099109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 10, 2013
Highlights
- Market Cap
- $290.60M
- Enterprise Value
- $265.81M
- EPS (TTM)
- -$1.11
- Total Revenue (TTM)
- $157.08M
- Gross Profit (TTM)
- $98.53M
- EBITDA (TTM)
- -$59.93M
- Year Range
- $1.19 - $4.64
- Target Price
- $6.00
- ROA (TTM)
- -32.29%
- ROE (TTM)
- -331.91%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MGNX Performance Chart
MacroGenics, Inc. (MGNX) is up 184.5% since the beginning of the year. At $5 per share, MGNX is trading just below its 52-week high of $5. Investors who bought $1,000 worth of MGNX shares 5 years ago would now be looking at an investment worth $179.
Loading charts...
Returns By Period
MacroGenics, Inc. (MGNX) has returned 184.47% so far this year and 249.62% over the past 12 months. Over the last ten years, MGNX has returned -15.31% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
MacroGenics, Inc.
- 1D
- 10.90%
- 1M
- 1.10%
- YTD
- 184.47%
- 6M
- 188.05%
- 1Y
- 249.62%
- 3Y*
- -7.25%
- 5Y*
- -29.11%
- 10Y*
- -15.31%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
MGNX Monthly Returns History
Based on dividend-adjusted daily data since Oct 10, 2013, MGNX's average daily return is +0.13%, while the average monthly return is +1.61%. At this rate, an investment would double in approximately 3.6 years.
Historically, 44% of months were positive and 56% were negative. The best month was May 2020 with a return of +167.2%, while the worst month was May 2024 at -72.3%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 14 months.
On a daily basis, MGNX closed higher 48% of trading days. The best single day was May 6, 2020 with a return of +230.9%, while the worst single day was May 10, 2024 at -77.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.66% | 8.74% | 45.23% | 6.57% | 35.06% | 10.10% | 184.47% | ||||||
| 2025 | -7.69% | -18.00% | -48.37% | 36.61% | -21.61% | -11.03% | 28.93% | 13.46% | -5.08% | -1.19% | -7.83% | 5.23% | -50.46% |
| 2024 | 48.65% | 25.45% | -17.95% | 0.41% | -72.33% | 3.91% | -11.53% | -6.65% | -6.27% | 11.25% | -1.91% | -9.47% | -66.22% |
| 2023 | -14.01% | 5.55% | 17.73% | -3.91% | -32.22% | 14.56% | -10.84% | -2.31% | -0.00% | 12.02% | 57.28% | 17.17% | 43.37% |
| 2022 | -23.05% | -24.29% | -5.78% | -18.84% | -51.47% | -14.99% | 6.10% | 26.84% | -12.85% | 47.98% | 25.59% | 4.35% | -58.19% |
| 2021 | -10.59% | 22.36% | 27.35% | 1.60% | -0.53% | -16.56% | -7.07% | -5.41% | -11.31% | -6.73% | -9.88% | -8.81% | -29.79% |
Benchmark Metrics
MacroGenics, Inc. has an annualized alpha of 13.94%, beta of 1.38, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since October 10, 2013.
- This stock participated in 161.93% of S&P 500 Index downside but only 51.97% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 13.94%
- Beta
- 1.38
- R²
- 0.05
- Upside Capture
- 51.97%
- Downside Capture
- 161.93%
Return for Risk
Risk / Return Rank
MGNX ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for MacroGenics, Inc. (MGNX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MGNX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.70 | ||
| Sortino ratioReturn per unit of downside risk | +1.09 | ||
| Omega ratioGain probability vs. loss probability | 1.41 | 1.37 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 7.36 | 2.78 | +4.57 |
| Martin ratioReturn relative to average drawdown | 16.28 | 12.44 | +3.84 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the MacroGenics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the MacroGenics, Inc. was 97.36%, occurring on Apr 4, 2025. The portfolio has not yet recovered.
The current MacroGenics, Inc. drawdown is 88.61%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -97.36%Apr 2025 | 11y 2mo | — | 12y 5moJan 2014 - now |
2013 bear market2013 | -23.38%Nov 2013 | 7d | 1mo 12d | 1mo 19dNov 2013 - Jan 2014 |
2013 pullback2013 | -7.46%Nov 2013 | 14d | 5d | 19dOct 2013 - Nov 2013 |
2013 pullback2013 | -4.18%Oct 2013 | 1d | 7d | 8dOct 2013 - Oct 2013 |
2013 pullback2013 | -3.86%Oct 2013 | 0s | 1d | 1dOct 2013 - Oct 2013 |
Drawdown Indicators
| MGNX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.36% | -56.78% | -40.58% |
Max Drawdown (1Y)Largest decline over 1 year | -34.16% | -9.10% | -25.06% |
Max Drawdown (3Y)Largest decline over 3 years | -95.06% | -18.90% | -76.16% |
Max Drawdown (5Y)Largest decline over 5 years | -96.31% | -25.43% | -70.88% |
Max Drawdown (10Y)Largest decline over 10 years | -97.02% | -33.92% | -63.10% |
Current DrawdownCurrent decline from peak | -88.61% | -1.80% | -86.81% |
Average DrawdownAverage peak-to-trough decline | -58.45% | -10.71% | -47.74% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.41% | 2.03% | +13.38% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of MacroGenics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how MacroGenics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MGNX relative to other companies in the Biotechnology industry. Currently, MGNX has a P/S ratio of 1.8. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MGNX in comparison with other companies in the Biotechnology industry. Currently, MGNX has a P/B value of 13.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MGNX
Add MacroGenics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MGNX